Genmab A/S to Post Q3 2024 Earnings of $0.35 Per Share, HC Wainwright Forecasts (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB) – HC Wainwright lifted their Q3 2024 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued to investors on Tuesday, August 27th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.35 for the quarter, up from their previous forecast of $0.34. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.13 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.41 EPS and FY2024 earnings at $1.39 EPS.

A number of other analysts have also issued reports on the company. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. BTIG Research upped their target price on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, Truist Financial increased their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, June 4th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $49.50.

Genmab A/S Price Performance

Genmab A/S stock opened at $27.89 on Wednesday. The firm’s 50 day simple moving average is $26.70 and its 200-day simple moving average is $28.15. Genmab A/S has a fifty-two week low of $24.53 and a fifty-two week high of $39.53. The company has a market cap of $18.44 billion, a P/E ratio of 23.24, a price-to-earnings-growth ratio of 1.01 and a beta of 0.97.

Institutional Trading of Genmab A/S

Several large investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. acquired a new stake in Genmab A/S in the 2nd quarter worth approximately $457,000. Cubist Systematic Strategies LLC raised its position in shares of Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after purchasing an additional 145,689 shares during the period. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after buying an additional 478 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after buying an additional 103,859 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its stake in Genmab A/S by 26.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after buying an additional 45,376 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.